Abstract:Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare and progressive disease caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase (TP). This results in a systemic accumulation of nucleosides and mitochondrial toxicity. AAV-based liver-directed gene therapy has shown efficacy in preclinical studies, but it has limitations such as a decline of transgene expression long-term. We propose that gene editing can circumvent some of these problems.Methods: We performed a preclinical study in the murine model of MNGIE to assess that the coordinated delivery of CRISPR/Cas9 and a TYMP cDNA caused the efficient integration of a TYMP transgene into introns of the Tymp and Alb loci in hepatocytes. CRISPR/Cas9 was delivered either as mRNA using nanoparticles or in AAV2/8 viral vectors; the latter were also used to package the TYMP cDNA. We assessed the efficient integration of the templates into the liver cells, and monitored the nucleoside levels in plasma to detect the biochemical correction.Findings: The best results were obtained using lipid nanoparticles. The consistent and stable nucleoside reduction observed correlated with the presence of TYMP mRNA and functional enzyme in the liver cells. In mice with an edited Alb locus, the transgene produced a hybrid Alb-hTP protein that was secreted, with high levels of TP activity in plasma.Interpretation: Liver-directed gene editing is a feasible approach to achieve the long-term biochemical correction of the disease, with several advantages over previous methods.Funding Information: This project was made possible with financial support from the Instituto de Salud Carlos III/FEDER (grant PI15/00172) and from MINECO/FEDER (grant RTI2018-094734-B-C22). The support of the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya, through SGR 2017 1559 grant, is also acknowledged.Declaration of Interests: S.H.Y.F. and Y.K.T. are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticle delivery systems for nucleic-acid-based drugs. RM was the recipient of personal fees associated with advisory tasks and of financial support from Modis Therapeutics for research outside the submitted work. RM also holds a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110), with royalties paid to Modis Therapeutics.INCOMPLETEEthics Approval Statement: All animal procedures were performed in accordance with European recommendations and were approved by our institutional ethics committee (Comitè Ètic d’Experimentació Animal).

A novel AAV9-dual microRNA-vector targeting GRIK2 in the hippocampus as a treatment for mesial temporal lobe epilepsy

GluK2 Is a Target for Gene Therapy in Drug-Resistant Temporal Lobe Epilepsy

Human pallial MGE-type GABAergic interneuron cell therapy for chronic focal epilepsy

Anti-seizure gene therapy for focal cortical dysplasia

Combinatorial gene therapy for epilepsy: Gene sequence positioning and AAV serotype influence expression and inhibitory effect on seizures

Gene therapy for epilepsy targeting neuropeptide Y and its Y2 receptor to dentate gyrus granule cells

A potassium leak channel silences hyperactive neurons and ameliorates status epilepticus

Systemic Delivery of Antagomirs During Blood-Brain Barrier Disruption is Disease-Modifying in Experimental Epilepsy

Global brain delivery of neuroligin 2 gene ameliorates seizures in a mouse model of epilepsy

AAV9-mediated targeting of natural antisense transcript as a novel treatment for Dravet Syndrome

Adenosine kinase gene modified mesenchymal stem cell transplantation retards seizure severity and associated cognitive impairment in a temporal lobe epilepsy rat model

Genome-wide Microrna Profiling of Plasma from Three Different Animal Models Identifies Biomarkers of Temporal Lobe Epilepsy.

Drug-Inducible Gene Therapy Effectively Reduces Spontaneous Seizures in Kindled Rats but Creates Off-Target Side Effects in Inhibitory Neurons

Adeno-Associated Viral Vectors in the Treatment of Epilepsy

Revoking the Seize Order: Preventing Spontaneous Seizures With AAV in a CLN2 Mouse Model

Potent and lasting seizure suppression by systemic delivery of antagomirs targeting miR-134 timed with blood-brain barrier disruption

Effective Gene Therapy for Metachromatic Leukodystrophy Achieved with Minimal Lentiviral Genomic Integrations

Pharmaco-genetic Therapeutics Targeting Parvalbumin Neurons Attenuate Temporal Lobe Epilepsy.

Brain Cell-Specific Origin of Circulating Microrna Biomarkers in Experimental Temporal Lobe Epilepsy

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE

Reactive A1 Astrocyte-Targeted Nucleic Acid Nanoantiepileptic Drug Downregulating Adenosine Kinase to Rescue Endogenous Antiepileptic Pathway.